Factors affecting S-homocysteinylation of LDL apoprotein B.
Materials and Methods
We purchased Hcy, Cys, oxidized CysGly, reduced Cys-Gly, glutathione, glutamylcysteine, [Na.sub.3]P[O.sub.4] x 12 [H.sub.2]O, [H.sub.3]B[O.sub.3], KBr, NaCl, [Na.sub.2]EDTA, N-methyl-D-glucamine, dimethyl sulfoxide, NN-dymethilphormamide, tri-n-butylphosphine, NaOH, 5-iodoacetamidofluorescein, and 5-sulfosalicylic acid (SSA) from Sigma; and chloroform, methanol, and acetonitrile from Carlo Erba. We used membrane filters (0.45 [micro]m) obtained from Millipore to filter all buffer solutions before capillary electrophoresis analysis. We used a Sephadex PD-10 column purchased from Amersham-Pharmacia.
We selected a total of 104 healthy persons of both sexes (44 men and 60 women, ages 13-79 years) who were recruited consecutively from the Laboratorio Generale di Medicina di Base, ASL 1 Sassari. All participants gave informed consent for participation in the study and for personal data management according to Italian laws. As confirmed by medical interviews, participants were not receiving dietary supplements of vitamin [B.sub.6], B12, folate, or drug therapy. Hypercholesterolemia and hyperhomocysteinemia were not exclusion criteria, because the aim of this study was to investigate the possible relationships between lipoprotein metabolism and thiols for both within reference interval and increased cholesterol and/or Hcy concentrations.
We collected blood into tubes containing EDTA. Plasma was prepared by centrifugation at 2000g for 10 min at 4[degrees]C. LDLs were isolated by ultracentrifugation according to methods described by Himber et al. (17) and McDowell et al. (18). Briefly, we added 0.9 mL of plasma to a centrifugation tube containing KBr (0.4451 g), adjusting the density of plasma to 1.300 g/L. This mixture was then overlaid with 2.1 mL of 150 mmol/L NaCl and centrifuged at 541 000g for 2 h at 4[degrees]C. LDL, VLDL, and HDL orange bands were recovered, and LDL was mixed (ratio, 1/1) with a solution containing KBr and EDTA 1% (density, 1.063 g/L) and centrifuged at 541000g for 2 h at 4[degrees]C.
apoB-BOUND THIOL PREPARATION AND QUANTIFICATION
We precipitated 200 [micro]g of LDL apoprotein with SSA (final concentration, 7.5%) and then centrifuged it at 2000g for 5 min. The protein pellet was washed twice with 500 [micro]L SSA 5% and once with 1 mL of acetonitrile/water (70/30) to remove SSA residue that could interfere with subsequent steps. After centrifugation, we discarded 950 [micro]L of supernatant and dried the apoprotein under decreased pressure in a Concentrator 5301 for 30 min at 60[degrees]C. After dissolving apoprotein in 200 [micro]L of 50 mmol/L NaOH at 60[degrees]C for 30 min, we reduced disulfide bonds by incubation with 20 [micro]L of 100 mL/L tri-n-butylphosphine in N,N-dymethilphormamide for 10 min, added 900 [micro]L of acetonitrile, vortex-mixed and centrifuged the solution at 2000g for 5 min, and then dried 1 mL of supernatant under decreased pressure at 60[degrees]C for 4 h. Dry samples were resuspended with 100 [micro]L of derivatization medium (0.08 mmol/L 5-iodoacetamidofluorescein, 25 mmol/L sodium phosphate buffer, pH 12.5). After 15 min at room temperature, derivatized samples were diluted 40 times in water and analyzed by capillary electrophoresis as previously described (15). Briefly, we used a 75-[micro]m i.d. and 57-cm-long (50 cm to the detection window) uncoated fused-silica capillary and performed analysis by applying 30 nL of sample under nitrogen pressure (0.5 psi for 5 s) in a mixture of 30 mmol/L sodium phosphate, 33 mmol/L boric acid, and 75 mmol/L N-methyl-D-glucamine, pH 11.3. The separating conditions (18 kV, 165 [micro]A at normal polarity) were reached in 20 s and were held at a constant voltage for 15 min. Separations were carried out at 40[degrees]C and monitored at 488 run excitation and 520 run emission wavelength.
TOTAL PLASMA THIOLS, PROTEIN, AND CHOLESTEROL ANALYSIS.
We measured total plasma thiols by capillary electrophoresis laser-induced detection as described by Zinellu et al. (19); apoB-100 protein content of the LDL fractions by the Lowry method; and total cholesterol, HDL cholesterol, and triglycerides by the enzymatic colorimetric method with commercial reagent sets (Roche Diagnostics).
The main biochemical variables of the 104 healthy volunteers analyzed as a whole and according to sex are shown in Table 1. As expected for a healthy population, 10% of the individuals enrolled in the study were hyperhomo-cysteinemic (Hcy, >15 [micro]mol/L). Men showed lower concentrations of HDL cholesterol and significantly higher concentrations of total plasma CysGly and Hcy than women. The sum of LMW thiols bound to apoprotein was higher in men than in women. In particular, men had significantly higher concentrations of apoB-CysGly, apoB-Hcy, and apoB-Cys. The distribution of plasma and LDL-bound thiols is shown in Fig. 1. Percentage values were calculated from the data reported in Table 1. The distribution of total plasma thiols differed substantially from that of LDL-bound thiols; in particular, the percentage of CysGly bound to apoB was higher than the percentage of the same thiol in plasma, and GSH concentrations were higher in the LDL fraction than in plasma. On the other hand, concentrations of the remaining thiols were significantly lower in lipoproteins than in plasma, and for apoprotein thiol distribution, only the apoB-bound Hcy percentage differed significantly in men vs women (2.70 vs 2.93%; P <0.01 data not shown). In Table 2, the concentrations and the relative amounts of plasma thiols bound to LDL are shown for all participants and according to sex. In 1 L of plasma, 0.522 [micro]mol of thiols (0.193% of total plasma thiols) are bound to LDL, The concentrations of apoB-bound Hcy are significantly lower in women than in men (0.0136 vs 0.0184 [micro]mol/L; P <0.01). The percentage values of thiols bound to LDL did not differ in women and men. Pearson correlation between Hcy concentrations contained in the LDL fraction and factors that could affect the amount of lipoproteins-bound Hcy (as CysGly, Hcy, Cys, GSH, G1uCys, total cholesterol, LDL, HDL and age) suggest that only total plasma Hcy is related to apoB-Hcy concentrations (P <0.0001). Using the stepwise multiple linear regression with LDL-Hcy as the dependent variable and sex, Cys, Hcy, CysGly, LDL, and HDL as independent variables, we found that total Hcy was the most important determinant of LDL-bound Hcy (t-test, 7.979; P <0.0001) but also a positive association with LDL (t-test, 2.068; P <0.041) and sex (t-test, 3.410; P <0.001) was found, whereas Cys (t-test, -1.986; P <0.046) and, mainly, CysGly (t-test, -4.003; P <0.0001) were negatively associated with apoB-Hcy concentrations.
Protein-mixed disulfide formation as a functional response to oxidative modification under pathologic or physiologic conditions is an important process in living organisms and takes place in all biological compartments. Plasma S-thiolated proteins have been detected in healthy humans, in patients with cardiovascular diseases, and in several cell types after oxidant exposure (20). Although increased protein S-thiolation is considered an in vivo marker of oxidative injury caused by noxious agents (21,22), the importance of this index in clinical studies has not been well documented. Thiols in plasma are mainly linked to albumin, but interactions between Hcy and ceruloplasmin, fibrin, and transthyretin have also been reported (23-25). These Hcy-mediated posttranslational modifications may have important functional consequences. In vitro studies have shown that homocysteinylation of the Cys9 residue of annexin II, the endothelial cell surface docking protein for tissue plasminogen activator, inhibits binding (26). Hcy also binds the fibrinbinding domain of plasma fibronectin in vitro, inhibiting its ability to bind fibrin (24), and binds factor Va in vitro, making it resistant to inactivation by activated protein C (27). Homocysteinylation appears to activate latent elastolytic metalloproteinase pro-MMP-2 by disulfide bond formation with the "Cys switch" on the propeptide (28). As with any other chemical reaction, the extent of Hcy protein derivative formation is dependent on time and concentration. The longer the exposure duration and the higher the concentrations of Hcy, the greater the biochemical damage inflicted. Furthermore, if the attacked molecules are long lived and the derivation reactions are irreversible, the harmful effects will be cumulative and clinical consequences progressive. Recent studies have demonstrated that plasma lipoproteins are also susceptible to S-homocysteinylation (14,15). At least 9 free sulfhydryl groups (-SH) in apoB-100 primary structure have been reported that could potentially bind plasma free aminothiols (13). Because lysyl residues of apoB could react in vivo with plasma HcyT by an amide bond, the number of these apoprotein sulfhydryl groups could increase considerably, thus increasing the number of sites that may be bound by plasma aminothiols (9). Even if we did not measure protein N-homocysteinylation concentrations, a 50 g/L LDL solution can be calculated to contain ~1 [micro]mol/L of Hcy-N-apoprotein, as recently reported by Jakubowski (29). Therefore, our apoB-100 samples should also be N-homocysteinilated proportionally to plasma tHcy concentrations (29, 30). Although each nanomole of apoB contains 9 nmol of free Cys residues (taking into account only native -SH of apoprotein and not those deriving from N-homocysteinylation), our data suggest that just few of these -SH sites are S-thiolated (~0.5 nmol/nmol apoB, as described in Table 1). Thus, apoproteins show less S-thiolation than expected from their free -SH content, and S-thiolation is probably limited by the accessibility of the same -SH residues. Hence, apoprotein N-homocysteinylation appears relevant to increase of new -SH sites available for the S-thiolation, but the importance of this finding remains to be elucidated.
Given that at least 5 LMW aminothiols occur in plasma, Hcy competes with other thiols for binding of susceptible -SH sites. Our results show that increasing concentrations of plasma Hcy lead to higher S-homocysteinylation of lipoprotein in vivo. These data, calculated with Pearson correlation analysis, were confirmed by multiple regression analysis, by which we also found that plasma Cys and CysGly both seem to inhibit interaction between Hcy and apoprotein. In particular, CysGly is a more effective competitor than Cys, although CysGly was present in plasma at 1/10th the concentration of Cys. Thus CysGly, which accounts for ~12% of total thiols in plasma, was more highly represented in the LDL fraction, making up -24% of all bound thiols. Because CysGly is a redox labile metabolite, it likely reacts more avidly with free -SH groups of apoB-100, acting as a physiologic inhibitor of Hcy-LDL linkage. Although total CysGly concentrations are higher in men than women, the Hcy/CysGly ratio is lower in women [women, 0.31 (0.1); men, 0.34 (0.1)], and although the difference is not statistically relevant (P = 0.14), it may account for the lower amount of Hcy bound to apoprotein in women.
By multiple regression analysis, we also found that LDL cholesterol concentrations may influence the quantity of Hcy bound to LDL. Increasing plasma cholesterol concentrations are related to increased interactions between Hcy and LDL apoprotein. Therefore, in hypercholesterolemia, a relatively higher quantity of thiols per gram of apoprotein may be transported within the LDL fraction. Apoprotein-bound thiols could be thus internalized by endothelial cells, degraded in lysosomes, and released in the cytosol, where they could alter the intracellular redox potential or modify intracellular proteins, causing endothelial dysfunction. It is known that LDL could pass, via transcytosis, through the vascular endothelium to reach the subendothelial space. Because increased concentrations of plasma LDL increase proportionally the rate of LDL entry (31) in hypercholesterolemic individuals, increased amounts of homocysteinilated LDL could accumulate in the intima. There, modified LDL could be avidly taken up from macrophages by membrane receptor or by phagocytosis, leading to intracellular cholesterol accumulation and foam cell formation (32). Finally, the increase of LDL Hcy suggests that LDL atherogenicity may be enhanced by the modification of its chemical and biological properties, leading to endothelial vascular injury and deposition of cholesterol, lipids, and Hcy in the intima space and the development of atherosclerotic plaques. CysGly could have a protective role decreasing the interaction between LDL apoprotein and Hcy, thus decreasing the amount of Hcy transferred from plasma to endothelial and subendothelial spaces. Further studies are required to better explain the kinetic reactions between Hcy and apoB-100, the inhibitory function of CysGly in this reaction, and the role of apoprotein-bound thiols in endothelial cell function.
This study was supported by the Assessorato dell'Igiene e Sanita Regione Autonoma della Sardegna and by the Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy. Language revision by Maria Antonietta Meloni is greatly appreciated.
(1.) Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19: 217-46.
(2.) Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey. Am Heart J 2000;139:446-53.
(3.) Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-72.
(4.) Thambyrajah J, Townend JN. Homocysteine and atherothrombosis--mechanisms for injury. Eur Heart J 2000;21:967-74.
(5.) Jakubowski H. Metabolism of homocysteine-thiolactone in human cell culture: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997;272:1935-42.
(6.) Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000;130:377-81.
(7.) Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13:2277-83.
(8.) McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-27.
(9.) Ferretti G, Bacchetti T, Moroni C, Vignini A, Nanetti L, Curatola G.
Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 2004;92: 351-60.
(10.) McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 2000;130:369-72.
(11.) Drunat S, Moatti N, Paul JL, Cogny A, Benoit M0, Demuth K. Homocysteine-induced decrease in endothelin-1 production is initiated at the extracellular level and involves oxidative products. Eur J Biochem 2001;268:5287-94.
(12.) Ferguson E, Hogg N, Antholine WE, Joseph J, Singh RJ, Parthasarathy S, Kalyanaraman B. Characterization of the adduct formed from the reaction between homocysteine-thiolactone and low density lipoprotein: antioxidant implications. Free Radic Biol Med 1999;26:968-77.
(13.) Yang C, Gu ZW, Yang M, Gotto AM Jr. Primary structure of apoB-100. Chem Phys Lipids 1994;67/68:99-104.
(14.) Zinellu A, Sotgia S, Deiana L, Carru C. Quantification of thiol-containing amino acids linked by disulfides to LDL. Clin Chem 2005;51:658-60.
(15.) Zinellu A, Sotgia S, Zinellu E, Formato M, Manca S, Magliona S, et al. Distribution of LDL-bound low molecular weight thiols: a new analytical approach. Electrophoresis 2006;27:2575-81.
(16.) Olszewski AJ, McCully KS. Homocysteine content of lipoproteins in hypercholesterolemia. Atherosclerosis 1991;88:61-8.
(17.) Himber J, Buhler E, Moll D, Moser UK. Low density lipoprotein for oxidation and metabolic studies. Isolation from small volumes of plasma using a tabletop ultracentrifuge. Int J Vitam Nutr Res 1995;65:137-42.
(18.) McDowell IF, McEneny J, Trimble ER. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. Ann Clin Biochem 1995;32:167-74.
(19.) Zinellu A, Carru C, Galistu F, Usai MF, Pes GM, Baggio G, et al. N-Methyl-D-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis 2003;24:2796-804.
(20.) Di Simplicio P, Franconi F, Frosali S, Di Giuseppe D. Thiolation and nitrosation of cysteines in biological fluids and cells. Amino Acids 2003;25:323-39.
(21.) Park EM, Park YM, Gwak Y. Oxidative damage in tissues of rats exposed to cigarette smoke. Rad Biol Med 1998;25:79-86.
(22.) Di Giuseppe D, Di Simplicio P, Capecchi PL, Lazzerini PE, Pasini FL. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med 2003;142:21-8.
(23.) Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 2001;276:46896-904.
(24.) Majors AK, Sengupta S, Willard B, Kinter MT, Pyeritz RE, Jacobsen DW. Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol 2002; 22:1354-9.
(25.) Lim A, Sengupta S, McComb ME, Theberge R, Wilson WG, Costello CE, et al. In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 2003;278:49707-13.
(26.) Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273:9987-93.
(27.) Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C J Biol Chem 2001;276:4389-97.
(28.) Bescond A, Augier T, Chareyre C, Garcon D, Homebeck W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999;263:498-503.
(29.) Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J Biol Chem 2002; 277:30425-8.
(30.) Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006;69:869-76.
(31.) Bratzler RL, Chisolm GM, Colton CK, Smith KA, Lees RS. The distribution of labelled low-density lipoprotein across the rabbit thoracic aorta in vivo. Atherosclerosis 1977;2:289-307.
(32.) Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 1994;4:70-7.
ANGELO ZINELLU,  * ELISABETTA ZINELLU,  SALVATORE SOTGIA,  MARILENA FORMATO,  GIAN MARIO CHERCHI,  LUCA DEIANA,  and CIRIACO CARRU  *
 Dipartimento di Scienze Biomediche, Cattedra di Biochimica Clinica, and
 Dipartimento di Scienze Fisiologiche, Biochimiche e Cellulari, University degli Studi di Sassari, Sassari, Italia.
 Nonstandard abbreviations: Hcy, homocysteine; HcyT, homocysteinethiolactone; Cys, cysteine; SSA, sulfosalicylic acid; CysGly, cysteinylglycine.
* Address correspondence to these authors at: Chair of Clinical Biochemistry, Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43/B, 07100 Sassari, Italy. Fax 39-079228120; e-mail angelozinellu@ libero.it (A.Z.), email@example.com (C.C.).
Received March 31, 2006; accepted August 29, 2006.
Previously published online at DOI: 10.1373/clinchem.2006.071142
Table 1. Mean biochemical parameters of studied population. All subjects, Men (44), mean (SD) mean (SD) Age, years 54.6 (16.1) 53.3 (15.6) Total cholesterol, mmol/L 5.271 (1.09) 5.069 (1.03) LDL cholesterol, mmol/L 3.261 (1.02) 3.165 (0.966) HDL cholesterol, mmol/L 1.40 (0.451) 1.31 (0.376) Triglycerides, mmol/L 1.274 (0.612) 1.405 (0.634) Plasma thiols Total LMW thiols, [micro]mol/L 275.9 (55.2) 286.3 (50.9) Total CysGly, [micro]mol/L 35.1 (7.0) 38.2 (8.2) Total Hcy, [micro]mol/L 11.05 (3.2) 12.43 (3.20) Total Cys, [micro]mol/L 221.7 (48.3) 227.9 (42.9) Total GSH, [micro]mol/L 4.88 (1.50) 4.60 (1.52) Total GluCys, [micro]mol/L (c) 3.11 (0.71) 3.16 (0.63) apoB-thiols apoB-Thiols, nmol/[micro]mol apoB 446 (104) 494 (106) apoB-CysGly, nmol/[micro]mol apoB 108 (22) 116 (25) apoB-Hcy, nmol/[micro]mol apoB 13.7 (6.2) 16.6 (7.5) apoB-Cys, nmol/[micro]mol apoB 324 (92) 349 (98) apoB-GSH, nmol/[micro]mol apoB 9.5 (3.7) 10.2 (4.5) apoB-GluCys, nmol/[micro]mol apoB 2.6 (0.4) 2.6 (0.4) Women (60), mean (SD) Age, years 56.4 (17.3) Total cholesterol, mmol/L 5.421 (1.11) LDL cholesterol, mmol/L 3.331 (1.05) HDL cholesterol, mmol/L 1.57 (0.474) (a) Triglycerides, mmol/L 1.180 (0.584) Plasma thiols Total LMW thiols, [micro]mol/L 268.3 (57.4) Total CysGly, [micro]mol/L 32.9 (4.8) (b) Total Hcy, [micro]mol/L 10.04 (2.88) (b) Total Cys, [micro]mol/L 217.2 (51.8) Total GSH, [micro]mol/L 5.09 (1.46) Total GluCys, [micro]mol/L (c) 3.07 (0.77) apoB-thiols apoB-Thiols, nmol/[micro]mol apoB 431 (95) (a) apoB-CysGly, nmol/[micro]mol apoB 103 (18) (a) apoB-Hcy, nmol/[micro]mol apoB 11.6 (4) (d) apoB-Cys, nmol/[micro]mol apoB 305 (88) (a) apoB-GSH, nmol/[micro]mol apoB 9.0 (3.0) apoB-GluCys, nmol/[micro]mol apoB 2.5 (0.4) (a) P <0.05. (b) P <0.0001. (c) GluCys, glutamylcysteine. (d) P <0.001. Table 2. Distribution of plasma thiols bound to LDL for all participants and after sorting for sex. (a) apoB-bound CysGly Hcy All participants (104) [micro]mol/L 0.125 (0.050) 0.0156 (0.0083) % 0.366 (0.159) 0.147 (0.086) Men (44) [micro]mol/L 0.131 (0.055) 0.0184 (0.0100) % 0.351 (0.136) 0.153 (0.087) Women (60) [micro]mol/L 0.121 (0.047) 0.0136 (0.0063) (b) % 0.377 (0.175) 0.143 (0.087) apoB-bound Cys GSH All participants (104) [micro]mol/L 0.367 (0.154) 0.0107 (0.0047) % 0.168 (0.075) 0.237 (0.111) Men (44) [micro]mol/L 0.392 (0.168) 0.0111 (0.0048) % 0.173 (0.073) 0.261 (0.101) Women (60) [micro]mol/L 0.352 (0.143) 0.0103 (0.0047) % 0.165 (0.076) 0.220 (0.116) apoB-bound GluCys (b) Total All participants (104) [micro]mol/L 0.0029 (0.0010) 0.522 (0.203) % 0.098 (0.039) 0.193 (0.082) Men (44) [micro]mol/L 0.0029 (0.0011) 0.555 (0.222) % 0.096 (0.034) 0.196 (0.078) Women (60) [micro]mol/L 0.0029 (0.0011) 0.500 (0.186) % 0.100 (0.043) 0.191 (0.086) (a) All values given as mean (SD). (b) GluCys, glutamylcysteine. (c) P <0 0.01 vs apoB-bound Hcy concentration in men. Fig. 1. Distribution of plasma and LDL-bound thiols of all patients. Plasma GluCys 1.14% CysGly 12.9% Hcy 4.02% Cys 80.1% GSH 1.83% ApoB GluCys 0.58% CysGly 24.4% Hcy 2.98% Cys 70.0% GSH 2.11% Note: Table made from pie chart.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Lipids, Lipoproteins and Cardiovascular Risk Factors|
|Author:||Zinellu, Angelo; Zinellu, Elisabetta; Sotgia, Salvatore; Formato, Marilena; Cherchi, Gian Mario; Dei|
|Date:||Nov 1, 2006|
|Previous Article:||Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease.|
|Next Article:||Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population.|